Drugs like Ozempic and Wegovy have had a meteoric rise in recent years, with benefits like weight loss and help with other health issues. But according to a recent study, those benefits fade within two years of patients stopping their treatment.
According to a study published in the BMJ, data from 9,341 obese or overweight patients treated in 37 studies with any of 18 different weight-loss drugs showed that they regained about one pound on average after stopping the drugs.
The same study said they were projected to return to their pre-treatment weight in about two years.
But weight was not the only thing that was projected to return after stopping the treatment. According to the same study, health risk factors like blood pressure and cholesterol levels, which saw benefits while taking the drugs, were projected to return to their old levels within 1.4 years.
GLP-1 medications tested as well
About half of the patients studied took newer GLP-1 drugs like semaglutide, sold as Ozempic and Wegovy, as well as tirzepatide, which is sold as Mounjaro and Zepbound. According to the study, the weight regain rate was faster for these drugs, with an average of 1.8 pounds per month.
“But because people on semaglutide or tirzepatide lose more weight in the first place, they all end up returning to baseline at approximately the same time,” study senior researcher Dimitrios Koutoukidis of Oxford University told Reuters.
Weight loss drugs have shown some success
Weight loss drugs like the ones tested in the study have shown large levels of success in the United States in recent years. Back in October 2025, a survey from the Gallup National Health and Well-Being Index showed that there were an estimated 7.6 million fewer obese people in the United States compared to 2022.
In 2022, the U.S. adult obesity rate was a record-high 39.9%, while in 2025, that rate gradually declined to 37%. While the obesity rate dropped, the usage of GLP-1 drugs like Ozempic and Wegovy doubled between 2025 and 2024, according to the same study.
Contributing: Nicole Fallert, USA TODAY; Reuters
Fernando Cervantes Jr. is a trending news reporter for USA TODAY. Reach him at [email protected] and follow him on X @fern_cerv_.
This article originally appeared on USA TODAY: Here's how fast you can gain weight after ending GLP-1, per study
LATEST POSTS
- 1
What is ‘Auld Lang Syne’? Why we sing this song at midnight on New Year’s Eve. - 2Can scientists detect life without knowing what it looks like? Research using machine learning offers a new way
- 3What's an atmospheric river? AP explains the weather phenomenon
- 4Scientists dove hundreds of feet into the ocean and found creatures no human has ever seen. Our trash beat us there
- 5'War is not over': Detailed diagrams of prisons found in cells of Oct. 7 terrorists
- 25 of the world’s best sandwiches
- Early Thanksgiving week forecast: Where Americans can expect cold, rain and snow for the holiday
- Beyond the habitable zone: Exoplanet atmospheres are the next clue to finding life on planets orbiting distant stars
- Benihana is 60 years old. Gen Z is lining up.
- I binged all 24 Hallmark Christmas movies in less than 30 days. I emerged a changed man.
- Procter & Gamble changes Crest toothpaste packaging to address Texas AG fluoride concerns
- 'Wicked: For Good' was filmed at this surreal National Park in Egypt
- Poll: 62% of Americans would oppose U.S. military action in Greenland
- Parents who delay baby's first vaccines also likely to skip measles shots
